gmp-orphan

gmp-orphan (GMPO) is a drug development company, incorporated in July 2011, selected by the bio-incubator Paris-Biotech Santé (France). GMPO targets to file, in unmet severe medical needs, 2 innovative drugs yearly from 2015 on. Our lead product, GMA-101, was the 1st neurology product ever to be granted a common EMA/FDA pre-IND procedure in 2012. GMPO’s R&D strategy is settled upon repositioning molecules already approved for other uses, what the US listed company Celgene Corp. did with thalidomide ($450m of sales in 2011). GMPO look at €250m in sales in 2018.